<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 16 Jun 2021 07:16:36 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>恒瑞医药ADC布局</title><link>https://mp.weixin.qq.com/s/UNfTB70MMSpo5apV88fc_Q</link><description></description><content:encoded><![CDATA[恒瑞医药ADC布局]]></content:encoded><pubDate>Wed, 16 Jun 2021 06:33:36 +0800</pubDate></item><item><title>湿性AMD新突破：小分子药物</title><link>https://mp.weixin.qq.com/s/C_Jsb7uxsBDxEGpbGkcG8A</link><description></description><content:encoded><![CDATA[湿性AMD新突破：小分子药物]]></content:encoded><pubDate>Wed, 16 Jun 2021 06:33:36 +0800</pubDate></item><item><title>特应性皮炎新突破：CCR4抑制剂</title><link>https://mp.weixin.qq.com/s/xek2HyveZwa68wurqIufng</link><description></description><content:encoded><![CDATA[特应性皮炎新突破：CCR4抑制剂]]></content:encoded><pubDate>Wed, 16 Jun 2021 06:33:36 +0800</pubDate></item><item><title>治疗实体瘤：表达CD3双抗的CAR-T</title><link>https://mp.weixin.qq.com/s/jsRKH-eQlDdWgHPUNcgn_Q</link><description></description><content:encoded><![CDATA[治疗实体瘤：表达CD3双抗的CAR-T]]></content:encoded><pubDate>Tue, 15 Jun 2021 07:00:54 +0800</pubDate></item><item><title>天境生物CD73抗体：寻求数十亿美元License-out合作</title><link>https://mp.weixin.qq.com/s/beHJ8odlk4TXj2Lr3Z3BvA</link><description></description><content:encoded><![CDATA[天境生物CD73抗体：寻求数十亿美元License-out合作]]></content:encoded><pubDate>Tue, 15 Jun 2021 07:00:54 +0800</pubDate></item><item><title>Novavax新冠三聚体蛋白疫苗媲美mRNA疫苗，三叶草生物在路上</title><link>https://mp.weixin.qq.com/s/JK5dtvoMRhkZ5b5cXGs6Lg</link><description></description><content:encoded><![CDATA[Novavax新冠三聚体蛋白疫苗媲美mRNA疫苗，三叶草生物在路上]]></content:encoded><pubDate>Tue, 15 Jun 2021 07:00:54 +0800</pubDate></item><item><title>南开大学张宏恺课题组：激动剂抗体、CD3双抗高通量筛选技术</title><link>https://mp.weixin.qq.com/s/U9OrlvUWbQqvKjOvTu_XTA</link><description></description><content:encoded><![CDATA[南开大学张宏恺课题组：激动剂抗体、CD3双抗高通量筛选技术]]></content:encoded><pubDate>Mon, 14 Jun 2021 11:12:45 +0800</pubDate></item><item><title>寡核苷酸药物递送技术</title><link>https://mp.weixin.qq.com/s/YaGis1Jy48pbYXz2c65CZg</link><description></description><content:encoded><![CDATA[寡核苷酸药物递送技术]]></content:encoded><pubDate>Mon, 14 Jun 2021 11:12:45 +0800</pubDate></item><item><title>医药笔记文章合集</title><link>https://mp.weixin.qq.com/s/5KEd4Af0yHctzuW1ZWFqtA</link><description></description><content:encoded><![CDATA[医药笔记文章合集]]></content:encoded><pubDate>Sun, 13 Jun 2021 07:00:34 +0800</pubDate></item><item><title>中国ADC竞争格局</title><link>https://mp.weixin.qq.com/s/h9D2dZzfVjGupmCfvTd2oA</link><description></description><content:encoded><![CDATA[中国ADC竞争格局]]></content:encoded><pubDate>Sat, 12 Jun 2021 06:13:12 +0800</pubDate></item><item><title>豪森药业大分子管线布局</title><link>https://mp.weixin.qq.com/s/WnQMgGgObcLyXi--5BAXNg</link><description></description><content:encoded><![CDATA[豪森药业大分子管线布局]]></content:encoded><pubDate>Fri, 11 Jun 2021 06:50:54 +0800</pubDate></item><item><title>王旭宇出任赛多利斯生物工艺解决方案中国区负责人</title><link>https://mp.weixin.qq.com/s/iCeJDeZbPGrMklxK9AFZoA</link><description></description><content:encoded><![CDATA[王旭宇出任赛多利斯生物工艺解决方案中国区负责人]]></content:encoded><pubDate>Fri, 11 Jun 2021 06:50:54 +0800</pubDate></item><item><title>4500万美元预付款：百济神州引进异体NK细胞疗法</title><link>https://mp.weixin.qq.com/s/L-nMyEEdKFxqkRA8KPmKyw</link><description></description><content:encoded><![CDATA[4500万美元预付款：百济神州引进异体NK细胞疗法]]></content:encoded><pubDate>Thu, 10 Jun 2021 06:09:10 +0800</pubDate></item><item><title>和元生物科创板IPO，基因治疗CDMO爆发增长</title><link>https://mp.weixin.qq.com/s/94JrAj4exeMoCJCGcndSNg</link><description></description><content:encoded><![CDATA[和元生物科创板IPO，基因治疗CDMO爆发增长]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:58:36 +0800</pubDate></item><item><title>国内首个！乐普生物TF ADC提交中国新药临床申请</title><link>https://mp.weixin.qq.com/s/mdBRdhoSgnCCoQb0KFF-BQ</link><description></description><content:encoded><![CDATA[国内首个！乐普生物TF ADC提交中国新药临床申请]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:58:36 +0800</pubDate></item><item><title>ASCO：跨国药企看点</title><link>https://mp.weixin.qq.com/s/DMldd4or9swuvKRVdKAj9g</link><description></description><content:encoded><![CDATA[ASCO：跨国药企看点]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:58:36 +0800</pubDate></item><item><title>亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂前景无限</title><link>https://mp.weixin.qq.com/s/dtGouCxDWCfsZkXwrBKS7w</link><description></description><content:encoded><![CDATA[亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂前景无限]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>Moderna 偏向性IL-2 mRNA启动临床研究</title><link>https://mp.weixin.qq.com/s/6wr9qpg7MwQ9SkWdupP-6g</link><description></description><content:encoded><![CDATA[Moderna 偏向性IL-2 mRNA启动临床研究]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>国内首家：健信生物申报PD-1/TIM-3双抗</title><link>https://mp.weixin.qq.com/s/uedxEvAS2Q1pBJ06ENd-xw</link><description></description><content:encoded><![CDATA[国内首家：健信生物申报PD-1/TIM-3双抗]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>Nature：纳米抗体攻克新冠突变体</title><link>https://mp.weixin.qq.com/s/-FcFdNqUxsIR65GJu1tWjw</link><description></description><content:encoded><![CDATA[Nature：纳米抗体攻克新冠突变体]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item></channel></rss>